利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.058 秒)

    Method of Diagnosing Asphyxia
    2.
    发明申请
    Method of Diagnosing Asphyxia 有权
    诊断窒息的方法

    公开(公告)号：US20120136581A1

    公开(公告)日：2012-05-31

    申请号：US13318797

    申请日：2010-05-04

    申请人： Matthias Keller ,  Hans-Peter Deigner ,  David Enot ,  Matthias Kohl ,  Ronnaug Solberg ,  Olga Didrik Saugstad ,  Therese Koal

    发明人： Matthias Keller ,  Hans-Peter Deigner ,  David Enot ,  Matthias Kohl ,  Ronnaug Solberg ,  Olga Didrik Saugstad ,  Therese Koal

    IPC分类号： G06F19/00

    CPC分类号： G01N33/6893 ,  G01N2800/12 ,  G06F19/24 ,  Y02A90/26

    摘要： A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.

    摘要翻译： 用于体外诊断与其相关的窒息和障碍的方法，体外估计患有窒息的患者的缺氧持续时间的方法和用于体外监测正常氧，缺氧和高氧条件和/或正常和高压氧治疗的方法 包括定量检测患者的生物样品中多种选自生物胺的窒息特异性内源性化合物; 肉碱衍生化合物; 氨基酸; 胆汁酸 羧酸; 类花生酸 脂质 胆固醇前体，胆固醇代谢物; 前列腺素 和糖。

    Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites.
    3.
    发明申请
    Method For Normalization in Metabolomics Analysis Methods with Endogenous Reference Metabolites. 审中-公开
    用内源性参考代谢物代谢组学分析方法进行正常化的方法。

    公开(公告)号：US20120208282A1

    公开(公告)日：2012-08-16

    申请号：US13381860

    申请日：2010-06-23

    申请人： Hans-Peter Deigner ,  Matthias Kohl ,  Matthias Keller ,  Therese Koal ,  David Enot

    发明人： Hans-Peter Deigner ,  Matthias Kohl ,  Matthias Keller ,  Therese Koal ,  David Enot

    IPC分类号： G01N27/62 ,  G01R33/465

    CPC分类号： G16B40/00 ,  G01N2800/60 ,  Y10T436/163333 ,  Y10T436/201666

    摘要： The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.

    摘要翻译： 本发明涉及内源性参考代谢物的使用以及对应于哺乳动物受试者的生物样品中所选靶标代谢物的量和/或浓度的强度数据的归一化方法，其中所述强度数据通过代谢组学分析法 与一种或多种内源性参考代谢物，包括在所述生物样品中进行所述选择的目标代谢物的至少一种体外代谢组学分析方法，同时在同一样品中进行一种或多种内源性参考代谢物的定量分析 或其衍生物，其中所述内源性参考代谢物是生物样品中以基本恒定水平存在于受试者中的这样的化合物; 并且其中所述内源性参考代谢物或其衍生物具有小于1500Da的分子量。

    Method for Predicting the likelihood of an Onset of an Inflammation Associated Organ Failure
    4.
    发明申请
    Method for Predicting the likelihood of an Onset of an Inflammation Associated Organ Failure 审中-公开
    预测炎症相关器官衰竭发生的可能性的方法

    公开(公告)号：US20120202240A1

    公开(公告)日：2012-08-09

    申请号：US13387572

    申请日：2010-07-23

    申请人： Hans-Peter Deigner ,  Matthias Kohl ,  David Enot ,  Theresa Koal ,  Matthias Keller

    发明人： Hans-Peter Deigner ,  Matthias Kohl ,  David Enot ,  Theresa Koal ,  Matthias Keller

    IPC分类号： G01N27/62 ,  G01R33/48 ,  G06F19/00 ,  H01J49/26 ,  G01N27/72

    CPC分类号： G01N33/6893 ,  G01N2800/26 ,  G16B5/00 ,  G16B40/00 ,  Y10T436/173845

    摘要： The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.

    摘要翻译： 本发明涉及用于通过受试者的定量代谢组学谱来预测来自哺乳动物受试者的体外生物样品的炎症相关器官功能衰竭发作的可能性的可靠和统计学上显着的方法，所述定量代谢组学特征包括多种内源性代谢物， 并将其与多种内源性器官衰竭预测目标代谢物的定量参考代谢组学谱进行比较，以便预测受试者是否可能或不可能发生器官功能衰竭。 此外，本发明涉及在这种方法中内源性器官衰竭预测目标代谢物的有用性。

    DIAGNOSING PROSTATE CANCER RELAPSE
    6.
    发明申请
    DIAGNOSING PROSTATE CANCER RELAPSE 审中-公开
    诊断前列腺癌相关

    公开(公告)号：US20120326025A1

    公开(公告)日：2012-12-27

    申请号：US13575903

    申请日：2011-01-28

    申请人： Klaus Weinberger ,  Hans-Peter Deigner ,  Emeka Ignatius Igwe ,  David Enot ,  Guido Dallmann ,  Helmut Klocker

    发明人： Klaus Weinberger ,  Hans-Peter Deigner ,  Emeka Ignatius Igwe ,  David Enot ,  Guido Dallmann ,  Helmut Klocker

    IPC分类号： H01J49/26

    CPC分类号： G01N33/57434 ,  G01N2800/54

    摘要： The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7α-Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5β,6β-Epoxycholesterol (5b,6b,EPC); 5g302,6g302-Epoxycholesterol (5a,6a,EPC); and 4β-Hydroxycholesterol (4BOHC); for prognosticating relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.

    摘要翻译： 本发明公开了使用选自由二酰基残基和C24：0（PCaa C24：0）组成的组的至少一种物质; 具有二酰基残基总数C40：3的磷脂酰胆碱（PC ae C40：3）; 具有二酰基残基的磷脂酰胆碱总数C40：4（PC ae C40：4）; 酰基残基总数为C26：0的溶血磷脂酰胆碱（lysoPC a C26：0）; 具有酰基残基的溶血磷脂酰胆碱和C6：0（溶血糖素a C6：0）; 13（S） - 羟基-9Z，11E-十八碳二烯酸（13S-HODE）; 12（S） - 羟基-5Z，8Z，10E，14Z-二十碳四烯酸（12S-HETE）; 15（S） - 羟基-5Z，8Z，11Z，13E-二十碳四烯酸（15S-HETE）; 白三烯B4（LTB4）; 前列腺素E2（PGE2）; 前列腺素D2（PGD2）; 7α-羟基胆固醇（7aOHC）; 7-酮胆固醇（7KC）; 5＆bgr;，6＆bgr; - 环氧胆固醇（5b，6b，EPC）; 5g302,6g302-环氧胆固醇（5a，6a，EPC）; 和4＆bgr; - 羟基胆固醇（4BOHC）; 用于预测PCa患者体液或组织样品中前列腺癌（PCa）的复发。